Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Lung Cancer: Independent Conference Coverage of the ASCO 2020 Scientific Meeting

Stephen V. Liu, MD
Zofia Piotrowska, MD, MHS
Released: September 25, 2020
Back Next

References

  1. Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. J Clin Oncol. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract LBA5.
  2. Kelly K, Altorki NK, Eberhardt WEE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non–small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33:4007-14.
  3. Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-125.
  4. Pennell NA, Neal JW, Chaft JE, et al. SELECT: A Phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor–mutant non–small-cell lung cancer. J Clin Oncol. 2019;37:97-104.
  5. Zhong W-Z, Wang Q, Mao W-M, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomized, open-label, phase 3 study. Lancet Oncol. 2018;19:139-148.
  6. Wu Y-L, Zhong W, Wang Q, et al. Gefitinib (G) versus vinorelbine + cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): a randomized, phase III trial (CTONG 1104). Program and abstracts of the 2017 Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2017; Chicago, Illinois. Abstract 8500.
  7. Wu Y-L, Zhong W, Wang Q, et al. CTONG1104: adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9005.
  8. Cortés ÁA, Urquizu LC, Cubero JH. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res. 2015;4:191-197.
  9. Peters S, Ramalingam SS, Paz-Ares L, et al. LBA4_PR: Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis. Ann Oncol. 2019;30(Suppl 5):LBA4_PR.
  10. Hellman MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093-2104.
  11. Ramalingam SS, Ciuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: three-year update from CheckMate 227 Part 1. J Clin Oncol. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9500.
  12. Reck M, Ciuleanu TE, Cobo Dols M, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate9LA. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Chicago, Illinois. Abstract 9501.
  13. Nivolumab [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2020.
  14. Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38:1505-1517.
  15. Adashek JJ, Subbiah IM, Matos I, et al. Hyperprogression and immunotherapy: fact, fiction, or alternative fact? Trends Cancer. 2020;6:181-191.
  16. Bendell JC, Bedard P, Bang Y-J, et al. CT302 - Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors. Program and abstracts of the 2020 American Association for Cancer Research Virtual Annual Meeting; June 22-24, 2020; Virtual. Abstract CT302.
  17. Rodríguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase III study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9503.
  18. ClinicalTrials.gov. A study of tiragolumab in combination with atezolizumab compared with placebo in combination with atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (SKYSCRAPER-01). Available at: https://clinicaltrials.gov/ct2/show/NCT04294810. Accessed August 30, 2020.
  19. Wang X and Zeng M. First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332). Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9508.
  20. Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomized, controlled, phase 2 study. Lancet Oncol. 2016:17:1672-1682.
  21. Li AM, Boichard A, Felip E, et al. New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Crit Rev Oncol Hematol. 2020;15:102990.
  22. Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38:124-136.
  23. Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 Study. J Clin Oncol. 2020;38:115-123.
  24. Gainor JF, Curigliano G, Kim D-W, et al. Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9515.
  25. Gainor JF, Lee DH, Curigliano G, et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). Program and abstracts of the 2019 Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2019; Chicago, Illinois. Abstract 9008.
  26. Selpercatinib [package insert]. Indianapolis, IN; Lilly USA, LLC; 2020.
  27. ClinicalTrials.gov. Clinical study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type advanced non-small cell lung cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02414139. Accessed August 30, 2020.
  28. Wolf J, Seto T, Han J-H, et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study. Program and abstracts of the 2019 Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2019; Chicago, Illinois. Abstract 9004.
  29. Capmatinib [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020.
  30. Wolf J, Overbeck TR, Han J-Y, et al. Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9509.
  31. ClinicalTrials.gov. DS-8201a in human epidermal growth factor receptor 2 (HER2)-expressing or -mutated non-small cell lung cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT03505710. Accessed August 30, 2020.
  32. Trastuzumab deruxtecan [package insert]. Basking Ridge, New Jersey: Daiichi Sankyo, Inc.; 2019.
  33. Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31:1997-2003.
  34. Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910-4918.
  35. Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9504.
  36. Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24:638-646.
  37. Neal J, Doebele R, Riely G, et al. Safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 in NSCLC. Program and abstracts of the 19th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC); September 23-26, 2018; Toronto, Canada. Abstract P1.13-44.
  38. Jänne PA, Neal JW, Camidge R, et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Program and abstracts of the 2019 Annual Meeting of the American Society of Clinical Oncology; May 31 - June 4, 2019; Chicago, Illinois. Abstract 9007.
  39. Le X, Goldman J, Clarke J, et al. Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study. Program and abstracts of the 2020 American Association for Cancer Research Virtual Annual Meeting; June 22-24, 2020; Virtual.. Abstract CT081.
  40. Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: results from a phase II basket trial. Program and abstracts of the 2019 Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2017; Chicago, Illinois. Abstract 8510.
  41. Atezolizumab [package insert]. South San Francisco, CA: Genentech, Inc; 2020.
  42. Durvalumab [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.
  43. Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.
  44. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929-1939.
  45. Rudin CM, Awad MM, Navarro A, et al. KEYNOTE-604: pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC). Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9001.
  46. Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-Line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38:2369-2379.
  47. Paz-Ares LG, Dvorkin M, Chen Y, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): updated results from the phase III CASPIAN study. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9002.
  48. Lurbinectedin [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2020.
  49. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645-654.
  50. Aix SP, Cote GM, Gonzalez AF, et al. Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumors: updated results from a phase Ib-II trial. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 3514.
  51. ClinicalTrials.gov. Study of irinotecan liposome injection (ONIVYDE®) in patients with small cell lung cancer (RESILIENT). Available at: https://clinicaltrials.gov/ct2/show/NCT03088813. Accessed August 30, 2020.
  52. Spigel DR, Paz-Ares L, Chen Y, et al. RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: subgroup analyses by platinum sensitivity. Program and abstracts of the 2020 Annual Meeting of the American Society of Clinical Oncology; May 29 - June 2, 2020; Virtual. Abstract 9069.
  53. Pralsetinib [package insert]. Cambridge, MA: Blueprint Medicines Corporation; 2020.
Back Next
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings